BTIG Reiterates Buy on Arcus Biosciences, Maintains $70 Price Target
Portfolio Pulse from richadhand@benzinga.com
BTIG analyst Kaveri Pohlman has reiterated a 'Buy' rating on Arcus Biosciences (NYSE:RCUS) and maintained a price target of $70.
August 23, 2023 | 2:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcus Biosciences has received a reiterated 'Buy' rating from BTIG, with a maintained price target of $70.
The 'Buy' rating from BTIG indicates a positive outlook for Arcus Biosciences. The maintained price target of $70 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100